While saliva‐based biomarkers show promise for detecting AD pathology, including Aβ, tau, pTau isoforms, NfL, GFAP, and lactoferrin, their clinical utility remains unknown, warranting future investigation. Here, GFAP is linked to Alzheimer disease.